Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Short Interest Update

Key Points

• Short interest surged 139.7% to 649,723 shares as of July 31, up from 271,067 shares on July 15. Short interest represented 0.2% of shares outstanding, but the low average trading volume produced an unusually high short-interest ratio of 2,578.3 days.
• Swedish Orphan Biovitrum shares opened at $48.20, near the company’s 52-week high of $49.03, with a market capitalization of $17.16 billion and a P/E ratio of 107.12.
• Analyst sentiment remains positive overall: four analysts rate the stock Buy and three rate it Hold, resulting in a “Moderate Buy” consensus rating, despite one recent downgrade to Hold.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 649,723 shares, a growth of 139.7% from the July 15th total of 271,067 shares. Based on an average daily volume of 252 shares, the short-interest ratio is presently 2,578.3 days. Currently, 0.2% of the company's stock are sold short.

Swedish Orphan Biovitrum Price Performance

Shares of Swedish Orphan Biovitrum stock opened at $48.20 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 0.20. The company has a market cap of $17.16 billion, a P/E ratio of 107.12 and a beta of 0.35. The firm's 50 day moving average price is $48.32 and its 200-day moving average price is $43.82. Swedish Orphan Biovitrum has a 52-week low of $28.93 and a 52-week high of $49.03.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BIOVF shares. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a "hold" rating in a research note on Monday, June 29th. Barclays restated an "overweight" rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. HC Wainwright began coverage on Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They issued a "buy" rating for the company. Finally, Zacks Research raised Swedish Orphan Biovitrum to a "hold" rating in a research report on Thursday, May 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy".

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi's strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company's marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source